See more : Mkango Resources Ltd. (MKA.V) Income Statement Analysis – Financial Results
Complete financial analysis of Ame Company For Medical Supplies (9527.SR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ame Company For Medical Supplies, a leading company in the Medical – Distribution industry within the Healthcare sector.
- Geotech Holdings Ltd. (1707.HK) Income Statement Analysis – Financial Results
- Nuvei Corporation (NVEI) Income Statement Analysis – Financial Results
- AOHATA Corporation (2830.T) Income Statement Analysis – Financial Results
- BTC Digital Ltd. (BTCT) Income Statement Analysis – Financial Results
- Zenotech Laboratories Limited (ZENOTECH.BO) Income Statement Analysis – Financial Results
Ame Company For Medical Supplies (9527.SR)
About Ame Company For Medical Supplies
Ame Company For Medical Supplies distributes and markets medical supplies for the aesthetic market in Saudi Arabia. Its products portfolio includes Teoxane, a range of injectable hyaluronic acid-based dermal fillers designed to treat wrinkles on the face and neck; medical laser systems and new therapies; botulinum products; Magellan, an autologous concentration system that delivers concentrated platelets and cells at the point of care; and MINT, an absorbable polydioxanone barbed suture indicated for use in soft tissue approximation. The company was founded in 2005 and is based in Jeddah, Saudi Arabia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 223.32M | 193.17M | 151.39M | 121.60M | 89.92M |
| Cost of Revenue | 124.57M | 102.89M | 81.84M | 66.62M | 48.26M |
| Gross Profit | 98.75M | 90.28M | 69.54M | 54.99M | 41.66M |
| Gross Profit Ratio | 44.22% | 46.74% | 45.94% | 45.22% | 46.33% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 2.92M | 6.51M | 4.53M | 0.00 | 0.00 |
| Selling & Marketing | 34.32M | 29.86M | 23.76M | 0.00 | 0.00 |
| SG&A | 60.73M | 36.37M | 28.29M | 32.40M | 25.34M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 61.47M | 60.31M | 45.03M | 32.40M | 25.34M |
| Cost & Expenses | 186.03M | 163.19M | 126.87M | 99.01M | 73.60M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 654.28K | 349.18K | 247.92K | 18.25K | 6.20K |
| Depreciation & Amortization | 1.54M | 853.51K | 458.86K | 291.86K | 108.51K |
| EBITDA | 39.77M | 30.99M | 24.84M | 22.88M | 16.43M |
| EBITDA Ratio | 17.81% | 16.17% | 16.46% | 18.82% | 18.27% |
| Operating Income | 37.29M | 29.98M | 24.51M | 22.59M | 16.32M |
| Operating Income Ratio | 16.70% | 15.52% | 16.19% | 18.58% | 18.15% |
| Total Other Income/Expenses | 297.05K | 57.67K | -304.90K | -18.25K | -6.19K |
| Income Before Tax | 37.58M | 30.03M | 24.21M | 22.57M | 16.31M |
| Income Before Tax Ratio | 16.83% | 15.55% | 15.99% | 18.56% | 18.14% |
| Income Tax Expense | 4.07M | 3.35M | 2.99M | 1.50M | 1.50M |
| Net Income | 33.52M | 26.68M | 21.22M | 21.07M | 14.81M |
| Net Income Ratio | 15.01% | 13.81% | 14.02% | 17.33% | 16.47% |
| EPS | 4.79 | 3.81 | 3.05 | 3.01 | 2.12 |
| EPS Diluted | 4.79 | 3.81 | 3.05 | 3.01 | 2.12 |
| Weighted Avg Shares Out | 7.00M | 7.00M | 6.96M | 7.00M | 7.00M |
| Weighted Avg Shares Out (Dil) | 7.00M | 7.00M | 6.96M | 7.00M | 7.00M |
Source: https://incomestatements.info
Category: Stock Reports